Type2 Diabetes
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
The landmark trial published in NEJM found Dexcom G7 users achieved 0.9% greater A1C reduction versus routine care, with five more hours…
-
FDA Approves Lilly’s Mounjaro, a Once-Weekly Dual-Action Drug for Type 2 Diabetes
Millions of Americans who live with type 2 diabetes now have an additional medication to consider. Tir tirzepatide, cleared by the U.S.…
Most read
-
Martin Lewis Warns Savers With £10,000 or More They Could Owe Tax on Interest
-
Asian & Oceanian Epilepsy Congress 2026 in Kuala Lumpur
-
Baby & Beyond Maternity Expo in Kuala Lumpur 2026
-
Axos Offers 5.00% Savings Rate for Six Months After Fed Hike, With Strings Attached
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
FDA orders class-wide GLP-1 label update for rare eye disease risk
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
-
Understanding Metastatic Prostate Cancer Prognosis and Modern Treatment Pathways
-
Nangibotide Targets Acute-on-Chronic Liver Failure With Phase 2 Data Due 2027
-
SABR Versus Surgery: New Study Reveals Mortality Gap for Early-Stage Lung Cancer
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992